B+
Bull case
20%
Probability
Target price
$1.60
+45.5% vs current
MYO
MyomoCNYSE American / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.90
-18.2% vs current
B-
Bear case
30%
Probability
Target price
$0.40
-63.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+28.0
Score
AI commentary
Sentiment is cautious-neutral. The March 9, 2026 disclosures improved the primary-source picture, but the thesis is still a monitoring view rather than a high-conviction turnaround: access expansion and recurring-source mix are promising, yet losses, Medicare concentration and financing dependence remain material. Deterministic signals also stay essentially neutral with only modest catalyst density.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 2026 results versus initial revenue guideHigh impact
The next operating checkpoint is whether Myomo can hit its Q1 2026 revenue guide of $9.0 million to $9.5 million while showing that recurring-source mix and referral efficiency are offsetting weaker advertising-driven demand; this matters because 2025 operating loss widened and management framed 2026 as a transition year [#PR-2026-03-09-Earnings] [#8-K-2026-03-09].
2026-06-30eventElevance network participation rollout through Q2 2026High impact
Myomo said its first Elevance Health network participation agreements are expected to become effective on a market-by-market basis through Q2 2026 and could add 45 million medical members, taking covered commercial lives to more than 80 million if fully implemented; evidence of actual market activation and referral conversion would be a meaningful reimbursement and access signal [#PR-2026-03-09-Elevance].
2026-12-31catalystRecurring-source mix and cash-burn improvement by 2H 2026High impact
Management is pushing toward more recurring patient sources, lower customer acquisition cost, lower material costs and slower opex growth, with the March 9 earnings release pointing to a roughly 20% material-cost reduction target by 2H 2026 and cash burn roughly halved versus 2025; the setup is meaningful, but execution risk is high given 2025 cash used in operations of $14.5 million and dependence on financing [#PR-2026-03-09-Earnings] [#10-K-2026-03-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology